As a result, the rates of thrombosis and other complications have improved compared to the pre-complement inhibitor era [5,11,13], leading to survival in PNH patients treated with C5 inhibitors approaching that of an age- and sex-matched general population [5]. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.